Literature DB >> 24240125

Nitric oxide drives embryonic myogenesis in chicken through the upregulation of myogenic differentiation factors.

Denise Cazzato1, Emma Assi1, Claudia Moscheni2, Silvia Brunelli3, Clara De Palma1, Davide Cervia4, Cristiana Perrotta5, Emilio Clementi6.   

Abstract

The muscle-specific variant of neuronal nitric oxide (NO) synthase (NOS-I), is developmentally regulated in mouse suggesting a role of NO during myogenesis. In chick embryo, a good model of development, we found that the expression of NOS-I is up-regulated, but only in the early phase of development. Through a pharmacological intervention in ovo we found that NO signalling plays a relevant role during embryonic development. The inhibition of NOS-I decreased the growth of embryo, in particular of muscle tissue, while the restoring of physiological NO levels, via administration of a NO donor, reversed this effect. We found a selective action of NO, produced by NOS-I, on regulatory factors involved in myogenic differentiation in the early phase of chick embryo development: inhibition of NO generation leads to a decreased expression of the Myocyte enhancer factor 2a (Mef2a), Mef2c, Myogenin and Myosin, which was reversed by the administration of a NO donor. NO had no effects on Myf5 and MyoD, the myogenic regulatory factors necessary for myogenic determination. The action of NO on the myogenic regulatory factors was mediated via generation of cyclic GMP (cGMP) and activation of the cGMP-dependent protein kinase G (PKG). Finally we found in myoblasts in vitro that the activation of Mef2c was the key event mediating the NO-induced modulation of myogenesis. Our results identify NO produced by NOS-I as a key messenger in the early phase of embryonic development of chicken, acting as a critical determinant of myogenesis through its physiological cGMP/PKG pathway.
© 2013 Published by Elsevier Inc.

Entities:  

Keywords:  1-[N-(2-aminoethyl)–N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate, DMEM, Dulbecco's Modified Eagle's Medium; 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; Chick embryo; DETA; FBS; GAPDH; HH; HRP; Hamburger and Hamilton; MRFs; Mef2; Mef2c; Murine myoblasts; Muscle development; Myocyte enhancer factor 2; N(ω)-propyl-l-arginine; NO; NO synthases; NOS; NOS-I; NPLA; ODQ; PBS; PKG; SDS; cGMP; cGMP-dependent protein kinase; cGMP/PKG; cyclic GMP; foetal bovine serum; glucose 6 phosphate dehydrogenase; horseradish-peroxidase; myogenic regulatory factors; neuronal NOS; nitric oxide; phosphate buffered saline; sGC; sodium dodecyl sulphate; soluble guanylate cyclase

Mesh:

Substances:

Year:  2013        PMID: 24240125     DOI: 10.1016/j.yexcr.2013.11.006

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  18 in total

1.  Putative Role of Ligands of DNIC in the Physiological Action of the Complex.

Authors:  V Yu Titov; A M Dolgorukova; A N Osipov; I I Kochish
Journal:  Bull Exp Biol Med       Date:  2021-10-07       Impact factor: 0.804

2.  S-Nitrosylated fetal hemoglobin in neonatal human blood.

Authors:  Daniel A Riccio; Jonathan R Malowitz; C Michael Cotten; Amy P Murtha; Timothy J McMahon
Journal:  Biochem Biophys Res Commun       Date:  2016-04-06       Impact factor: 3.575

3.  Modulation of Acid Sphingomyelinase in Melanoma Reprogrammes the Tumour Immune Microenvironment.

Authors:  Emma Assi; Davide Cervia; Laura Bizzozero; Annalisa Capobianco; Sarah Pambianco; Federica Morisi; Clara De Palma; Claudia Moscheni; Paolo Pellegrino; Emilio Clementi; Cristiana Perrotta
Journal:  Mediators Inflamm       Date:  2015-05-26       Impact factor: 4.711

4.  Hormones and immunity in cancer: are thyroid hormones endocrine players in the microglia/glioma cross-talk?

Authors:  Cristiana Perrotta; Clara De Palma; Emilio Clementi; Davide Cervia
Journal:  Front Cell Neurosci       Date:  2015-06-23       Impact factor: 5.505

5.  Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers.

Authors:  Maria Vittoria Cossu; Dario Cattaneo; Serena Fucile; Paolo Pellegrino; Sara Baldelli; Valeria Cozzi; Amedeo Capetti; Emilio Clementi
Journal:  Drug Des Devel Ther       Date:  2014-05-02       Impact factor: 4.162

6.  Deficient nitric oxide signalling impairs skeletal muscle growth and performance: involvement of mitochondrial dysregulation.

Authors:  Clara De Palma; Federica Morisi; Sarah Pambianco; Emma Assi; Thierry Touvier; Stefania Russo; Cristiana Perrotta; Vanina Romanello; Silvia Carnio; Valentina Cappello; Paolo Pellegrino; Claudia Moscheni; Maria Teresa Bassi; Marco Sandri; Davide Cervia; Emilio Clementi
Journal:  Skelet Muscle       Date:  2014-12-12       Impact factor: 4.912

7.  Climacostol reduces tumour progression in a mouse model of melanoma via the p53-dependent intrinsic apoptotic programme.

Authors:  Cristiana Perrotta; Federico Buonanno; Silvia Zecchini; Alessio Giavazzi; Francesca Proietti Serafini; Elisabetta Catalani; Laura Guerra; Maria Cristina Belardinelli; Simona Picchietti; Anna Maria Fausto; Simone Giorgi; Enrico Marcantoni; Emilio Clementi; Claudio Ortenzi; Davide Cervia
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

8.  Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors.

Authors:  Mario Tirone; Valentina Conti; Fabio Manenti; Pier Andrea Nicolosi; Cristina D'Orlando; Emanuele Azzoni; Silvia Brunelli
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

9.  Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin.

Authors:  Davide Cervia; Emma Assi; Clara De Palma; Matteo Giovarelli; Laura Bizzozero; Sarah Pambianco; Ilaria Di Renzo; Silvia Zecchini; Claudia Moscheni; Chiara Vantaggiato; Patrizia Procacci; Emilio Clementi; Cristiana Perrotta
Journal:  Oncotarget       Date:  2016-05-03

10.  Inhibitory effect of MyoD on the proliferation of breast cancer cells.

Authors:  Changjing Cai; Xiaoqun Qin; Ziyi Wu; Qixia Shen; Wenqian Yang; Shujun Zhang; Jinling Duan; Fenglan Liang; Chi Liu
Journal:  Oncol Lett       Date:  2016-04-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.